59,223 Enliven Therapeutics, Inc. $ELVN Shares Sold by Candriam S.C.A.

Candriam S.C.A. decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 6.5% during the third quarter, HoldingsChannel.com reports. The firm owned 846,451 shares of the company’s stock after selling 59,223 shares during the quarter. Candriam S.C.A.’s holdings in Enliven Therapeutics were worth $38,943,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter valued at $38,000. State of Wyoming bought a new position in shares of Enliven Therapeutics in the second quarter worth about $96,000. Sterling Capital Management LLC increased its stake in Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock worth $88,000 after buying an additional 1,771 shares during the period. FNY Investment Advisers LLC purchased a new position in Enliven Therapeutics in the 2nd quarter worth about $126,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Enliven Therapeutics during the third quarter worth approximately $172,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Trading Up 10.4%

ELVN opened at $49.43 on Friday. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The stock has a fifty day moving average price of $47.25 and a 200-day moving average price of $43.08.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ELVN shares. Barclays started coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research cut Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Finally, JPMorgan Chase & Co. started coverage on Enliven Therapeutics in a research report on Thursday, October 1st. They set an “overweight” rating and a $75.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $75.44.

Insider Activity

In other Enliven Therapeutics news, Director J. Scott Garland sold 13,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,462,240. This represents a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 31,054 shares of company stock worth $1,493,823 in the last quarter. 3.00% of the stock is owned by insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.